Osteal Therapeutics Presents Positive Six-Month Results from the APEX Clinical Trial Program at the 34th Annual Musculoskeletal Infection Society Meeting
05 août 2024 12h28 HE
|
Osteal Therapeutics
DALLAS, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Osteal Therapeutics, Inc. (“Osteal”), a clinical-stage biopharmaceutical company developing a new category of combination drug/device therapies for...
Kaerus Bioscience Announces Initiation of Phase 1 Clinical Trial for its Novel BK Channel Modulator KER-0193 being developed for Fragile X Syndrome
25 juil. 2024 05h00 HE
|
Kaerus Bioscience
LONDON, July 25, 2024 (GLOBE NEWSWIRE) -- Kaerus Bioscience Ltd. (www.kaerusbio.com), a clinical-stage biotechnology company focused on developing therapeutics for rare genetic syndromes of...
[Latest] Global Glycomics Market Size/Share Worth USD 5.2 Billion by 2033 at a 13.6% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
05 juil. 2024 03h30 HE
|
Custom Market Insights
Austin, TX, USA, July 05, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Glycomics Market Size, Trends and Insights By Product Type (Reagents, Enzymes,...
Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024
02 juil. 2024 16h05 HE
|
Avid Bioservices, Inc
-- Recorded Fourth Quarter Revenue of $43.0 Million – Highest in Company History -- -- Signed $30 Million in Net New Business Resulting in Backlog of $193 Million -- -- New Mammalian and Cell and...
Osteal Therapeutics Closes $50M Series D Financing to Support Approval and Commercial Launch of Lead Candidate
05 juin 2024 09h00 HE
|
Osteal Therapeutics
Osteal Therapeutics secured $50M in Series D financing led by Zimmer Biomet. The funds will advance VT-X7, a treatment for periprosthetic joint infection.
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
23 mai 2024 08h05 HE
|
Avid Bioservices, Inc
TUSTIN, Calif., May 23, 2024 (GLOBE NEWSWIRE) -- Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient...
[Latest] Global Non-Small-Cell Lung Cancer Drug Market Size/Share Worth USD 68,888.6 Million by 2033 at a 8.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
21 mai 2024 03h30 HE
|
Custom Market Insights
Austin, TX, USA, May 21, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Non-Small-Cell Lung Cancer Drug Market Size, Trends and Insights By Cancer Type...
[Latest] Global Lipid Nanoparticles Market Size/Share Worth USD 1,899.8 Million by 2033 at a 14.1% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
02 mai 2024 04h30 HE
|
Custom Market Insights
Austin, TX< USA, May 02, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “Lipid Nanoparticles Market Size, Trends and Insights By Type (Nano-Structured...
[Latest] Global 3D Cell Culture Market Size/Share Worth USD 4.6 Billion by 2033 at a 11.3% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth, Growth Rate, Value)
18 avr. 2024 12h30 HE
|
Custom Market Insights
Austin, TX, USA, April 18, 2024 (GLOBE NEWSWIRE) -- Custom Market Insights has published a new research report titled “3D Cell Culture Market Size, Trends and Insights By Product (Scaffolds Based 3d...
Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) Proteins
09 avr. 2024 15h34 HE
|
Revolution Medicines, Inc.
REDWOOD CITY, Calif., April 09, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted...